JPRN-UMIN000044038
Completed
未知
An Open-Label, Expanded Access Program with Nivolumab (ONO-4538) for cancer of unknown primary (CUP) (NivoCUP-2) Biomarker study (WJOG14620MTR) - WJOG14620MTR
ConditionsCancer of unknown primary
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Cancer of unknown primary
- Sponsor
- West Japan Oncology Group
- Enrollment
- 49
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
ivoCUP-2JPRN-jRCT2051200146akagawa Kazuhiko60
Completed
Not Applicable
An Open-Label, Expanded Access Program With Lenvatinib for the First Line Treatment of Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaJPRN-jRCT2080223705Eisai Co., Ltd.30
Completed
Phase 2
An Open-Label, Non-Comparative Expanded Access Study of the Raf-Kinase Inhibitor Sorafenib as a Subsequent to First-Line Therapy in Patients with Advanced Renal Cell CarcinomaAdvanced renal cell carcinomaCancer - Renal Cell CarcinomaACTRN12606000140550Austin Health75
Completed
Not Applicable
Trastuzumab deruxtecan for subjects with HER2 mutated metastatic NSCLCJPRN-jRCT2071220096eno Shizuko30
Active, not recruiting
Phase 1
Clinical Study with the bispecific antibody Blinatumomab in pediatric and adolescent subjects with B-precursor Acute Lymphoblastic Leukemia (ALL) who did not respond to previous therapy or who relapsed after initial successful previous therapyEUCTR2014-001700-21-DEAmgen Inc.100